You Don't Know JAK in IBD

Epidemiology of IBD

Burden of Disease

Factors Contributing to Pathogenesis of IBD

CD and UC Are Progressive

CD and UC Are Progressive (cont)

Immunopathogenesis of IBD

Goals of IBD Therapy

Treat to Target

FDA-Approved Therapies for IBD

Limitations of Current IBD Treatments

New and Emerging Treatments in IBD

Tofacitinib

Tofacitinib in Adults With UC OCTAVE 1 and 2 Studies

Tofacitinib in CD

Investigational JAK Inhibitors in IBD

Filgotinib in Moderate to Severe CD FITZROY Study Results

Upadacitinib in Moderate to Severe CD Celest Study Results

IL-12/-23 Antagonists

Selective Adhesion Molecule Inhibitors

S1P Receptor Modulators

S1P Receptor Modulators (cont)

Other Emerging Therapies in IBD

Concluding Remarks

Abbreviations

Abbreviations (cont)